ETOPOSIDE

SBRT

Shanghai Chest HospitalSmall moleculePhase 2Dormant

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 89/ 100

Competitive context

4 Active assets in the SBRT cohort.

Asset / Sponsor	Phase	Rating
Rivoceranib Fujian Cancer Hospital	Phase 2	CCC
CIS-DIAMMINEDICHLOROPLATINUM II Shanghai Chest Hospital	Phase 2	CCC
Vinorelbine Shanghai Chest Hospital	Phase 2	CCC
Benmelstobart Nanfang Hospital, Southern Medical University	Phase 2	CCC
Catequentinib Nanfang Hospital, Southern Medical University	Phase 2	CCC

View all 10 →

Same molecule, other indications

ETOPOSIDE is also rated in:

acute megakaryoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

acute monocytic leukemiaDormant

BBB

Indicative ·

79 / 100

acute myeloblastic leukemia with maturationDormant

BBB

Indicative ·

79 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.